• Aliases: ISIS 481464, ISIS-STAT3rx (tentative US brand name)
    • An antisense oligonucleotide targeting STAT3, leading to apoptosis and reduced tumor cell growth
    • Currently under investigation in phase 1/2 clinical trial with advanced cancers
    • Recommended phase 2 dose: 2 mg/kg IV LD on MWF, then Q weekly
    • Proposed tissue half-life: 20 days
    • Possible side effects: Thrombocytopenia, liver dysfunction
    (Furqan et al., 2013)
    Other topics in Targeted and Immunotherapy Agents